The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
5FU/LV with or without irinotecan in patients with resected stage II-III rectal cancer: Final analysis of R98 intergroup study.
Catherine Delbaldo
No relevant relationships to disclose
Marc Ychou
No relevant relationships to disclose
Ayman Zawadi
No relevant relationships to disclose
Jean-Yves Douillard
No relevant relationships to disclose
Thierry André
No relevant relationships to disclose
Veronique Guerin-Meyer
No relevant relationships to disclose
Céline Lepère
No relevant relationships to disclose
Olivier Dupuis
No relevant relationships to disclose
Roger Faroux
No relevant relationships to disclose
Annie Jouhaud
No relevant relationships to disclose
Emmanuel Quinaux
No relevant relationships to disclose
Pascal Piedbois
No relevant relationships to disclose